Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

CUSIP: 45719W205

Q2 2026 13F Holders as of 30 Jun 2026

Holder snapshot 6 signals
Share change
+2,742,253
SEC-reported price per share
$2.03
Number of holders
106
Value change
+$6,935,350
Number of buys
66
Number of sells
36
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
135,127,605

Security key

45719W205

Report period

Q2 2026

Institutions

106

Top holders

10

Ownership snapshot

Top reported holders of IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Commodore Capital LP
Disclosed value leader
Sands Capital Life Scienc...
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G 13F 3/4/5 Lead comparable stake: 9.9% 13D/G row: Commodore Capital LP Showing 1-6 of 15 holder rows.

Quick read

Commodore Capital LP leads the comparable SEC ownership view at 9.9%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Commodore Capital LP's linked filing trail.
Comparable ownership Top 5
Commodore Capital LP 9.9%
ADAR1 Capital Management, LLC 9.9%
Fairmount Funds Management LLC 9.9%
Sands Capital Life Sciences Pulse... 9.3%
PERCEPTIVE ADVISORS LLC 6.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Commodore Capital LP
13D/G 13F
Company
9.9%
$25,439,441
14,054,940 shares
$0 31 Mar 2026
ADAR1 Capital Management, LLC
13D/G 13F
Company
9.9%
$25,086,651
13,860,028 shares
+$2,113,430 31 Mar 2026
Fairmount Funds Management LLC
13D/G 13F
Company
9.9%
$24,922,202
12,461,101 shares
+$10,885,052 31 Dec 2025
Sands Capital Life Sciences Pulse Fund II, L.P.
13D/G 3/4/5
10%+ Owner
9.3%
$26,558,689
13,018,965 shares
$0 30 Jun 2026
PERCEPTIVE ADVISORS LLC
13D/G 13F
Company
6.9%
$21,054,585
10,320,875 shares
-$4,722,600 30 Jun 2026
Trails Edge Capital Partners, LP
13D/G 13F
Company
6.1%
$14,583,794
8,057,345 shares
+$3,460,986 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
106
Shares
117,857,873
Rows available
106
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
104
Q2 2026 holders
106
Holder diff
2
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .